Masimo (NASDAQ:MASI) Sets New 52-Week High – Should You Buy?

Masimo Co. (NASDAQ:MASI) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $184.51 and last traded at $179.93, with a volume of 107652 shares. The stock had previously closed at $180.36.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MASI shares. Stifel Nicolaus reissued a “buy” rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Raymond James boosted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Piper Sandler increased their price objective on Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, January 22nd. Finally, Wells Fargo & Company upped their price target on Masimo from $171.00 to $193.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $191.40.

Masimo Stock Up 1.1 %

The stock has a 50-day moving average of $172.65 and a 200-day moving average of $150.39. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company has a market cap of $9.76 billion, a PE ratio of 125.79 and a beta of 1.02.

Institutional Trading of Masimo

A number of large investors have recently modified their holdings of the business. Smartleaf Asset Management LLC raised its stake in Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 64 shares during the last quarter. Blue Trust Inc. raised its position in shares of Masimo by 56.3% during the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 71 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Masimo by 0.8% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 9,815 shares of the medical equipment provider’s stock worth $1,622,000 after acquiring an additional 82 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in Masimo by 0.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 10,456 shares of the medical equipment provider’s stock worth $1,728,000 after acquiring an additional 83 shares in the last quarter. Institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.